載入...
Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial
BACKGROUND: Angiogenesis and activation of the epidermal growth factor (EGFR) pathway play an essential role in tumor proliferation and metastasis. Targeting angiogenesis or EGFR alone does not yield adequate tumor control in most solid tumors. Overcoming intrinsic and/or acquired resistance may nee...
Na minha lista:
| 發表在: | Exp Hematol Oncol |
|---|---|
| Main Authors: | , , , , , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
BioMed Central
2020
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7171918/ https://ncbi.nlm.nih.gov/pubmed/32337094 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40164-020-00159-1 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|